Loading...

ALMS ALUMIS INC Product Launches 8-K Filing

LMS

LMS

ALUMIS INC

(ALMS)

2025 8-K

Clinical Trial Update

Financial Results Announced

Stock Offering Announced

New Drug Results

Financial Results Update

Investor Presentation Update

Financial Results Announced

Merger of Equals

Merger of Equals

Merger of Equals

Financial Statements

Merger Agreement

Collaboration Agreement

Financial Results

Clinical Trial Results

Merger Confirmation

Merger Agreement

External Links:

On March 8, 2025, Alumis Inc. announced positive 52-week data from its Phase 2 clinical trial for ESK-001 in psoriasis, presented at the AAD Annual Meeting in Orlando, Florida.

AI Assistant

ALUMIS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.